Prospera Energy (PEI.V)’s big corporate evolution: From incompetence to dishonesty
Brera Holdings (BREA.Q) pioneering pubco sports investment model, but is it a win?
“The markets are dead!”: Emerita Resources (EMO.V) shows otherwise with massive upside coming
Lithium Ionic (LTH.V) is up 50% in 3 months, and is moving toward production
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public markets pitfalls.
Today, we return to Filament Health (FH.NEO), a Canadian-based psychedelics company focusing on the natural extraction of psilocybin with clinical grade formulations, exact dosages and enhanced drug delivery.
Enjoy!
Filament Health (FH.NEO) – Investor Roundtable Video #7